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Abstract
AIM: To study the institutional experience over 8 years 
with 200 continuous-flow (CF) - left ventricular assist 
devices (LVAD).
METHODS: We evaluated our institution’s LVAD data-
base and analyzed all patients who received a CF 
LVAD as a bridge to transplant (BTT) or destination 
therapy from March 2006 until June 2014. We identified 
200 patients, of which 179 were implanted with a 
HeartMate II device (Thoratec Corp., Pleasanton, CA) 
and 21 received a Heartware HVAD (HeartWare Inc., 
Framingham, MA).
RESULTS: The mean age of our LVAD recipients 
was 59.3 years (range 17-81), 76% (152/200) were 
males, and 49% were implanted for the indication 
of BTT. The survival rate for our LVAD patients at 30 
d, 6 mo, 12 mo, 2 years, 3 years, and 4 years was 
94%, 86%, 78%, 71%, 62% and 45% respectively. 
The mean duration of LVAD support was 581 d (range 
2-2595 d). Gastrointestinal bleeding (was the most 
common adverse event (43/200, 21%), followed by 
right ventricular failure (38/200, 19%), stroke (31/200, 
15%), re exploration for bleeding (31/200, 15%), 
ORIGINAL ARTICLE
Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.4330/wjc.v7.i11.792
792 November 26, 2015|Volume 7|Issue 11|WJC|www.wjgnet.com
World J Cardiol 2015 November 26; 7(11): 792-800
ISSN 1949-8462 (online)
© 2015 Baishideng Publishing Group Inc. All rights reserved.
World Journal of 
CardiologyW J C
Retrospective Study
ventilator dependent respiratory failure (19/200, 9%) 
and pneumonia (15/200, 7%). Our driveline infection rate 
was 7%. Pump thrombosis occurred in 6% of patients. 
Device exchanged was needed in 6% of patients. On 
multivariate analysis, preoperative liver dysfunction, 
ventilator dependent respiratory failure, tracheostomy and 
right ventricular failure requiring right ventricular assist 
device support were significant predictors of post LVAD 
survival.
CONCLUSION: Short and long term survival for patients 
on LVAD support are excellent, although outcomes still 
remain inferior compared to heart transplantation. The 
incidence of driveline infections, pump thrombosis and 
pump exchange have declined significantly in recent 
years. 
Key words: Left ventricular assist device; Outcomes; 
Heart failure; Continuous-flow
© The Author(s) 2015. Published by Baishideng Publishing 
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Core tip: In this paper, we report our experience over 
the last 8 years with implanting continuous-flow left 
ventricular assist devices (LVADs). The aim of this 
analysis is to identify common occurring complications 
after LVAD implantation and identify areas for potential 
improvement in both patient management and sele-
ction. This is the largest single institutional LVAD 
experience that has been published, to the best of our 
knowledge.
Tsiouris A, Paone G, Nemeh HW, Borgi J, Williams CT, Lanfear 
DE, Morgan JA. Short and long term outcomes of 200 patients 
supported by continuous­flow left ventricular assist devices. 
World J Cardiol 2015; 7(11): 792­800  Available from: URL: 
http://www.wjgnet.com/1949­8462/full/v7/i11/792.htm  DOI: 
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INTRODUCTION
Continuous-flow left ventricular assist devices (CF 
LVADs) are now the standard treatment for patients 
with end stage heart failure refractory to medical 
management[1-3]. The shortage of heart donors and 
the overall minimal therapeutic impact of heart trans-
plantation on advanced heart failure have certainly 
accelerated the recent advances made in LVAD tech-
nology. In 2001, the landmark REMATCH trial demon-
strated superiority of the pulsatile-flow HeartMate XVE 
vs best medical management, although these devices 
were still limited by their large size, reduced durability, 
significant and frequent postoperative complications[4]. 
Newer generation CF LVAD has by and large overcome 
most of the limitations of the pulsatile devices. Following 
the HeartMate II (HM II) trial[1], continuous flow devices 
were approved by the FDA, initially for bridge to 
transplantion (BTT) and subsequently for destination 
therapy (DT). Increasing clinical implementation and a 
multidisciplinary approach between cardiac surgeons 
and cardiologists to postoperative LVAD therapy have in 
recent years further improved LVAD outcomes. Despite 
these significant advances, LVAD implantations are still 
associated with significant morbidity, especially in the 
early postoperative period[5,6]. Improvements are still 
required if LVADs are to become a plausible alternative 
to heart transplantation or a therapeutic option for 
less sick patients in earlier stages of heart failure. The 
aim of our study was to investigate our institution’s 
8-year experience with CF LVADs and to analyze short 
and long term results with a goal to identify areas of 
improvement.
MATERIALS AND METHODS
This retrospective study was approved by our health 
system’s Institutional Review Board. We reviewed our 
institution’s LVAD dataset and analyzed all patients who 
received a CF LVAD as a BTT or DT from March 2006 
until June 2014. We identified 200 patients, of which 
179 were implanted with a HeartMate II device (Thoratec 
Corp., Pleasanton, CA) and 21 received a Heartware 
HVAD (HeartWare Inc., Framingham, MA).
Patient data
Multiple patient comorbidities from our LVAD database 
were analyzed. Pre and postoperative hemodynamic 
measurements were also evaluated. Finally we exa-
mined post LVAD related complications. We defined 
ventilator dependent respiratory failure (VDRF) as 
inability to extubate after 7 d right ventricular (RV) 
failure was considered for patients who needed a RVAD 
or who required inotropes in excess of two weeks in 
order to support the RV. Defining acute renal failure, 
was based on the RIFLE criteria (two fold increase in 
creatinine or a decline in glomerular filtration rate by 
half.
Statistical analysis
Patient data were compared between patients who 
received LVAD as DT or BTT using chi-squared tests 
for nominal data and Wilcoxon two-sample tests for 
continuous variables. Nominal data were reported as 
count and percent whereas as mean and standard 
deviations were calculated for continuous variables. For 
counts that were not large, the fisher exact tests were 
utilized. Kaplan Meier curves were used to generate 
estimates of survival and Cox proportional hazards 
models were used to assess the various covariates effect 
on survival. A backward stepwise routine was used 
to generate the most parsimonious model where all 
variables included were significant. Statistical significance 
was considered P < 0.05. SAS 9.2 was utilized for our 
analysis.
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RESULTS
Preoperative patient demographics and operative 
characteristics
The mean age of our LVAD recipients was 59.3 years 
(range 17-81), 76% (152/200) were males and 
24% females (48/200). BTT was the indication for 
LVAD implantation in 49% of patients (98/200) and 
DT in 51% (102/200) of patients. Additional patient 
demographics and comorbidities are presented in 
Table 1. In terms of operative characteristics, 31% of 
patients had undergone previous median sternotomy, 
the average cardiopulmonary bypass time was 113 
min, cross clamp time (when used) was 71 min, and 
19% of patients underwent a concomitant procedure 
at the time of LVAD implantation. In our cohort, 18% 
were on some type of mechanical circulatory support 
(MCS) at the time of LVAD insertion. Types of pre CF 
LVAD MCS included intraortic balloon pumps (23/36, 
63%), pulsatile flow HeartMate XVE (5/36, 15%), 
794 November 26, 2015|Volume 7|Issue 11|WJC|www.wjgnet.com
CentriMag devices (5/36, 15%), Impella (2/26, 8%) 
and AbioMed support (1/36, 3%). BTT patients were 
significantly younger, had worse pre LVAD liver function 
and albumin, whereas DT patients were more likely to 
be diabetic, to have PVD, CRI and to have undergone 
previous cardiac surgery. Pre-LVAD inotropic support or 
MCS was more likely in the BTT patients (Table 1). 
Duration of support, heart transplant and survival rates
The mean duration of LVAD support was 581 d (range 
2-2595 d) (Table 2). A 56-year-old male, who received 
a CF LVAD for DT, is our longest survivor having been 
on LVAD therapy for just over 7 years. Overall, 27% of 
LVAD recipients and 46% of the BTT patient underwent 
heart transplantation (Table 2). At 2 years, the survival 
rate for our heart transplant recipients was 95% (52/55) 
which was significantly superior to the 2 year 71% 
survival rate for DT patients (P = 0.02). The survival 
rate at 30 d, 6 mo, 12 mo, 2 years, 3 years and 4 
years was 94%, 86%, 78%, 71%, 62% and 45% 
  Variable Total (n  = 200) BTT (n  = 98) DT (n  = 102) P  value
  Age (yr) 54.3 ± 12.5  50.1 ± 12.8  58.4 ± 10.7 0.001
  Gender
     Female 24% (48/200) 25.5% (25/98) 22.8% (23/102)
     Male 76% (151/200) 74.5% (73/98) 76.5% (78/102) 0.652
  Race
     AA 46% (92/200) 39.8% (39/98) 52% (53/102) 0.375
     Caucasian 54% (108/200) 54.1% (53/98) 42.4% (47/102)
  Etiology of heart failure
     ICM 52% (104/200) 29% (28/98) 74.5% (76/102) 0.001
     NIDCM 48% (96/200) 51% (50/98) 45.1% (46/102)
     BSA 1.97 ± 0.27 1.96 ± 0.27 1.98 ± 0.28 0.667
     BMI 28.3 ± 5.5  28.1 ± 4.3  28.5 ± 6.5 0.763
     Albumin (g/dL) 4.14 ± 10.03 3.19 ± 0.51  5.06 ± 14.05 0.015
     DM 46% (92/200) 38.8% (38/98) 52.9% (54/102) 0.038
     HTN 83% (166/200) 79.6% (78/98) 86.2% (88/102) 0.153
     CRI 40% (81/200) 29.6% (29/98) 51% (52/102) 0.002
     Dialysis 2.5% (5/200) 3.1% (3/98) 1.8% (2/102)         0.680
     COPD 15.5% (31/200) 15.3% (15/98) 15.7% (16/102) 0.917
     PVD 12% (23/200) 7.1% (7/98) 15.7% (16/102) 0.055
     Vented 12% (25/200) 9.2% (9/98) 15.7% (16/102) 0.134
     Previous cardiac surgery 32% (63/200) 20.4% (20/98) 42% (43/102) 0.001
     Creatinine (mg/dL) 1.42 ± 0.62 1.43 ± 0.58 1.42 ± 0.65 0.869
     AST (U/L) 48.3 ± 82.8 58.0 ± 106.8 38.9 ± 45.7 0.212
     ALT (U/L) 46.5 ± 78.5 59.8 ± 99.4 33.5 ± 47.3 0.002
     CPB time (min) 113.5 ± 46.1 109.5 ± 46.0 117.8 ± 46.1 0.178
     XCL time (min) 71 ± 30.6 85.2 ± 33.7 51.7 ± 26.0 0.054
     MCS at time of VAD 18% (36/200) 24% (23/98) 13% (13/102) 0.051
     On inotropes at time of VAD 75%(150/200) 81% (80/98) 69% (70/102) 0.036
     Pre VAD CVP (mmHg) 11.8 ± 6.4  11.6 ± 6.4 12.0 ± 6.4 0.653
     Pre VAD PAPs (mmHg) 51.4 ± 14.2  50.5 ± 14.5 52.3 ± 13.8 0.412
     Pre VAD PAPd (mmHg) 24.5 ± 9.2 24.4 ± 9.8 24.7 ± 8.5 0.682
     Pre Vad CI (L/min per square metre) 1.85 ± 0.51 1.87 ± 0.54 1.83 ± 0.47 0.961
     Pre VAD PCWP (mmHg) 23.0 ± 9.6 22.7 ± 9.8 23.4 ± 9.4 0.463
     Blood transfusions 23% (46/200) 18% (18/98) 27% (28/102)         0.250
     Concomitant cardiac procedure 19% (39/200) 23% (23/98) 15% (16/102) 0.137
Table 1  Patient demographics and comorbidities
BTT: Bridge to transplant; DT: Destination therapy; ICM: Ischemic cardiomyopathy; NIDCM: Non ischemic dilated cardiomyopathy; BSA: Body surface 
area; BMI: Body mass index; DM: Diabetes mellitus; HTN: Hypertension; CRI: Chronic renal insufficiency; COPD: Chronic obstructive pulmonary disease; 
PVD: Peripheral vascular disease; AST: Aspartate transaminase; ALT: Alanine aminotransferase; CPB: Cardiopulmonary bypass; XCl: Cross clamp; MCS: 
Mechanical circulatory support; VAD: Ventricular assist device; CVP: Central venous pressure; PAP: Pulmonary artery systolic pressure; PAPd: Pulmonary 
artery diastolic pressure; CI: Cardiac index; PCWP: Pulmonary capillary wedge pressure.
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of 63 patients have died. Causes of death included: 
stroke (20/63, 32% of which 15 /63, 24% were 
hemorrhagic and 5/63, 8% were ischemic, range 2-654 
d postoperatively, median 35 d), sepsis (17/63, 27%, 
range 5-320 d postoperatively, median 47 d), multi-
organ failure (15/63, 24%, range 4-211 d median 
35 d), right ventricular failure (6/63, range 2-139 d, 
median 10 d), refractory arrhythmia (2/63, 3%, at 64 
and 128 d after LVAD implantation), bowel perforation 
(1/63, 1.5%, on postoperative day-11 and day-13), 
disconnection from the power source (1/63, 1.5%, 14 
respectively (Figure 1). Survival rates were similar for 
BTT and DT patients (P = 0.566). Survival at 1 mo, 6 
mo, 1 year, 2 years, 3 years and 4 years for the BTT 
patients was 93%, 87%, 70%, 70%, 63% and 52% 
respectively whereas for the DT group survival was 
95%, 85%, 78%, 71%, 58% and 40% respectively 
(Figure 2). Competing outcomes of BTT vs DT patients 
is demonstrated in Table 3.
Causes of death
Since implanting our first CF LVAD in 2006, a total 
  Variable Total (n  = 200) BTT (n  = 98) DT (n  = 102) P  value
  Postoperative ICU stay (d) 195 10.7 ± 10.4 95 10.2 ± 7.7 100 11.2 ± 12.5 0.833
  Overall length of stay (d) 198 21.4 ± 14.3 98 20.8 ± 12.9 100 22.1 ± 15.6 0.517
  Readmitted within 30 d 26.5% (53/200) 26.0 (25/96) 27% (28/102) 0.725
  Reexploration for bleeding 15% (31/200) 10% (10/98) 5% (6/102)              0.040
  DL infection 7% (15/200) 9% (9/98) 5% (6/102) 0.386
  Pocket infection 1% (2/200) 1% (1/98) 1% (1/102) 0.493
  Pneumonia 7% (15/200) 9% (9/98) 5% (6/102) 0.375
  Hemorrhagic stroke 10% (21/200) 9% (9/98) 11% (12/102) 0.432
  Emboli stroke 5% (10/200) 6% (6/98) 3% (4/102) 0.493
  VDRF 9% (19/200) 10% (10/98) 8% (9/102) 0.774
  Tracheostomy 2% (5/200) 1% (1/98) 3% (4/102) 0.369
  Dialysis 2% (5/200) 3% (3/98) 1% (2/102)              0.680
  GIB 21% (43/200) 17% (17/98) 25% (26/102) 0.289
  Reoperation for Al 2% (4/200) 4% (4/98) 0% (0/102) 0.058
  RV failure 19% (38/200) 15% (15/98) 22% (23/102) 0.192
  RV failure requiring milrinone 13% (26/200) 9% (9/98) 16% (17/102) 0.103
  RV failure requiring RVAD 6% (12/200) 6% (6/98) 5% (6/102) 0.803
  Heart transplant  27% (55/200) 45% (45/98) 10% (10/102) 0.001
  Duration of support (d) 581.0 ± 517.9 554.8 ± 535.0 606.4 ± 502.1 0.253
Table 2  Postoperative outcomes
ICU: Intensive care unit; DL: Driveline; VDRF: Ventilator dependent respiratory failure; GIB: Gastrointestinal bleeding; AI: Aortic insufficiency; RV: Right 
ventricular; RVAD: Right ventricular assist device.
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Figure 1  Kaplan-Meier survival curve for all patients receiving continuous-flow left ventricular assist devices. LVAD: Left ventricular assist device.
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BTT and DT patients in terms of LOS, ICU stay and 
readmission (Table 2). The most common cause of 30 
d readmission were cardiac related (chest pain, SOB/
heart failure, arrhythmia), gastrointestinal bleeding 
(GIB) (25%), infections 12% (pneumonia, wound/ 
driveline infections, UTI) and stroke 8%.
Hemodymanic measurements pre LVAD and post LVAD 
at 6 mo
Hemodynamic measurements prior to LVAD implantation 
and after 6 mo of LVAD therapy are demonstrated 
in Table 4. Significant improvement was noted for all 
indices and measurements, which confirmed adequate 
LV decompression and improvement in RV function.
Predictors of survival
Univariate analysis showed that pre-LVAD renal (HR 
= 1.56; 95%CI: 1.11-2.21, P = 0.012) and hepatic 
function (HR = 1.03; 95%CI: 1.01-1.05, P = 0.004), 
length of ICU stay (HR = 1.34; 95%CI: 1.12-1.61, P = 
0.001), the occurrence of VDRF (HR = 4.66; 95%CI: 
2.51-8.67, P = 0.001), the need for tracheostomy 
(HR = 15.18; 95%CI: 5.56-41.4, P = 0.001) and the 
occurrence of post LVAD RV failure that required RVAD 
support (HR = 5.81; 95%CI: 2.84-11.9, P = 0.001) 
were significant predictors of survival. Variables with a 
P < 0.25 were included in a cox regression model. On 
multivariate analysis, pre LVAD liver function, VDRF, 
tracheostomy and implantation of a RVAD for RV failure 
still predicted survival (Table 5).
DISCUSSION
Continuous flow LVADs have now become an efficient 
mo after implantation), and pump thrombosis (1/63, 
1.5%, 18 mo after implantation). 
Postoperative LVAD complications
Post LVAD complications are listed in Table 2. GIB was 
the most common adverse event (43/200, 21%), 
followed by RV failure (38/200, 19%), stroke (31/200, 
15%), re exploration for bleeding (31/200, 15%), 
VDRF (19/200, 9%) and pneumonia (15/200, 7%). 
Our driveline infection rate was 7%. Pump thrombosis 
occurred in 6% of patients. Device exchanged was 
needed in 6% of patients, of which 77% (10/13) 
were for pump thrombosis and 13% (3/13) for severe 
driveline and pocket infections. No differences were 
noted between BTT and DT patients in terms of adverse 
events.
Length of ICU and hospital stay, and early readmissions
The average length of hospital stay (LOS) for our LVAD 
patients was 21 d, of which 11 d were spent in the 
intensive care unit (ICU). Readmissions within 30 d 
of index hospitalization discharge occurred in 27% of 
patients. No differences were observed between the 
Variable Patients (%)
  BTT Died 28.6 (28/98)
Ongoing 25.5 (25/98)
Transplant 45.9 (45/98)
  DT Died   34.3 (35/102)
Ongoing   54.8 (56/102)
Transplant     9.8 (10/102)
Table 3  Outcomes for bridge to transplan and destination 
therapy patients
LVAD Kaplan-Meier BTT and DT comparison
With number of subjects at risk
+ Censored
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Figure 2  Comparison of Kaplan-Meier survival between bridge to transplan and destination therapy patients. LVAD: Left ventricular assist device; BTT: Bridge 
to transplan; DT: Destination therapy.
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liver function. VDRF and trachesotomy both indicate 
critical illness and prolonged ICU support which are also 
expected to be predictors of poor outcome.
Several major centers around the world have 
also reported excellent survival outcomes, analogous 
to those reported in our study. A multi-institutional 
analysis from the United Kingdom and Germany[11] 
published survival rates of 89% at 30 d, 76% at 1 year 
and 66% at 2 years, from 139 CF LVAD implantations 
over a 6-year period. The average duration of support 
in this study was 514 d. No differences were identified 
between HeartMate II and HeartWare devices in terms 
of survival, although there was a trend towards more 
transfusions in the HeartMate group. These findings 
match our results when comparing the two types of 
devices. John et al[12] from the University of Minnesota 
published their single institutional experience with 130 
CF LVADs. Overall, 30 d, 6 mo, and 1 year survival 
was 95.1%, 83.5%, and 78.8%, respectively. Driveline 
infections (25%), GIB 18% and stroke were the most 
common adverse events. 
Possibly the most common and hazardous adverse 
events of the old generation pulsatile flow LVADs 
were resistant pocket/driveline infections and pump 
thrombosis[4,13,14]. Both these complications resulted 
in frequent device exchanges. Newer generation 
devices are more reliable and durable and fortunately 
these events are less frequent with CF LVADs[15-17], as 
clearly demonstrated in our study. Device exchange 
was performed in 6% of our patients, of which 77% 
(10/13) were for pump thrombosis and 13% (3/13) 
treatment for patients with end stage heart failure for 
the indication of BTT or DT, with excellent short and 
long term survival, as demonstrated in this study. 
Our analysis showed that after CF LVAD implantation, 
survival at 30 d was 94%, at 1 year 78%, at 2 year 
71%, and at 4 years 45%. Our longest survivor has 
been on LVAD therapy for over 7 years. Although 
these results by far surpass outcomes of patients with 
advanced heart failure on medical therapy, they are still 
inferior to heart transplantation which remains the gold 
standard for treating ESHF[7]. At 2 years the survival 
rate for our heart transplant recipients was 95% (52/55), 
which was superior to the 2 year 71% survival rate 
for DT patients (P = 0.02). Apart from improvement 
in survival, LVAD patients benefit from improved 
peripheral perfusion which certainly enhances quality of 
life. As demonstrated in our hemodynamic and ECHO 
measurements, 6 mo of LV therapy is associated with 
adequate LV decompression, significant improvement in 
RV function and in end organ perfusion. This is achieved 
with close postoperative surveillance and by obtaining 
regular echocardiograms to assess for aortic ejection, LV 
decompression, positions of the inteventricular septum, 
right ventricular function, and for residual mitral and 
tricuspid regurgitation[5]. We aim to maintain a flow 
index (CI) > 2.2 L/min per square metre. We also 
regularly adjust revolutions per minute (rpm) speed to 
achieve adequate flow, LV decompression, peripheral 
perfusion, and end organ function.
Our multivariate analysis demonstrated that preo-
perative liver dysfunction, and postoperative VDRF, 
tracheostomy, and RV failure requiring RVAD support 
were significant predictors of post LVAD mortality. These 
variables have previously been reported as potential risk 
factors for early post LVAD death in several published 
series[8-10]. High preoperative LFTs are an indication of 
poor end organ perfusion and RV dysfunction, which 
are certainly expected to increase postoperative mor-
tality. These patients are coagulopathic, which cause 
postoperative bleeding, tamponade, and makes fluid 
management more challenging, especially with RV 
dysfunction which frequently co-exists with abnormal 
  Variables Pre VAD Post VAD P value
  CVP (mmHg) 12 ± 6      8 ± 4.5 0.001
  PAPs (mmHg)   53.52 ± 13.76   36.03 ± 11.85 0.001
  PAPd (mmHg) 26.15 ± 9.50 16.11 ± 6.24 0.001
  CI (L/min per square meter)   1.78 ± 0.39   2.52 ± 0.60 0.001
  PCWP (mmHg)   25.09 ± 10.05 11.93 ± 7.84 0.001
  LVEDD (mm)   71.70 ± 13.61 57.45 ± 15.3 0.001
  LVEF (%)     16 ± 7.90      21 ± 9.00 0.017
Table 4  Hemodymanic measurements pre and post left 
ventricular assist device at 6 mo
VAD: Ventricular assist device; CVP: Central venous pressure; PAP: 
Pulmonary artery systolic pressure; PAPd: Pulmonary artery diastolic 
pressure; CI: Cardiac index; PCWP: Pulmonary capillary wedge pressure; 
LVEDD: Left ventricular end diastolic diameter; LVEF: Left ventricular 
ejection fraction.
  Variable HR 95%CI P  value Backwards stepwise model
  Albumin 0.64 (0.27, 1.52) 0.310
  Length of stay 0.85 (0.62, 1.17) 0.319
  CPB time 1.05 (0.98, 1.14) 0.175
  CRI 1.13 (0.44, 2.91) 0.804
  PVD 0.95 (0.30, 3.03) 0.931
  Vented 0.93 (0.17, 4.97) 0.929
  Creatinine 0.77 (0.37, 1.63) 0.495
  PreVAD AST 1.03 (1.00, 1.07) 0.072 1.03 (1.01, 1.05) 0.01
  PreVAD ALT 1.02 (1.00, 1.05) 0.064 1.02 (1.01, 1.04) 0.02
  Blood transfusion 1.19 (0.45, 3.14) 0.732
  ICU stay 0.80 (0.52, 1.24) 0.320
  Reexploration 1.70 (0.50, 5.79) 0.794
  VDRF   4.92 (1.62, 14.93) 0.005 3.05 (1.41, 6.59) 0.005
  Tracheostomy   5.53 (0.65, 46.78) 0.116  4.54 (1.35, 15.32) 0.015
  RV failure 0.45 (0.09, 2.26) 0.330
  RVAD   8.90 (1.30, 61.06) 0.066 3.64 (1.59, 8.36) 0.002
  Age  1.02 (0.95, 1.12 ) 0.176
  Gender  0.75 (0.66, 1.56 ) 0.321
  Resternotomy 1.31 (0.83, 4.55) 0.673
  Etiology of 
  heart failure
1.23 (0.59, 4.08) 0.512 
Table 5  Multiple cox proportional hazard models
CPB: Cardiopulmonary bypass; CRI: Chronic renal insufficiency; PVD: 
Peripheral vascular disease; AST: Aspartate transaminase; ALT: Alanine 
aminotransferase; ICU: Intensive care unit; VDRF: Ventilator dependent 
respiratory failure; RV: Right ventricular; RVAD: Right ventricular assist 
device.
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causes a leftward shift of the interventricular septum, 
which reduces its contractility thus impairing RV 
function[28]. It is also challenging for the RV to keep up 
with the sudden increase in LV output which further 
decreases RV function. In addition, subtle changes in 
the pulmonary microcirculation before and after LVAD 
implantation also add to RV dysfunction[19,23]. We have 
previously published the patients who develop post 
LVAD RV failure and only require inotropic support with 
Milrinone, have equivalent outcomes to patients without 
RV failure[29]. It is only when RVAD support is required, 
does the morbidity and mortality increase, which is 
clearly demonstrated in our current study. Although 
certain risk factors predicting RV failure and RVAD 
support after LVAD implantation have been described, 
such as renal and liver failure, leucocytosis, high CVP/
PCWP ratio, high CVP and decreased right ventricular 
stroke work index, predicting severe RV failure still 
remains a challenge[29-31].
Two types of LVADs have been implanted at our 
institution, HMII and HVAD. Of the 200 LVADs, 179 
were HMII and 21 were HVADs. These devices have 
similarities and divergences. The HMII is an axial flow 
pump with an electromagnetically suspended rotor. 
The larger HMII device requires an additional pump 
pocket formation in the upper abdominal preperitoneal 
space[32]. The HVAD is a centrifugal flow pump, chara-
cterized by a smaller size, which allows for its placement 
within the pericardial cavity[33]. Although the number 
of HVADs we implanted was insufficient to generate 
results for meaningful conclusions, so far we haven’t 
identified a significant difference in the overall mortality 
rate (32% for HMII vs 23% for HVADs, P = 0.301) or 
other complications. There only appeared to be a higher 
rate of blood transfusions with the HMII (20% vs 9%), 
which possibly corresponds to the need to form a pump 
pocket. Nevertheless, the higher transfusion rate did not 
correspond with higher incidences of re-exploration for 
bleeding and had no significant impact on survival.
An area of controversy and discussion amongst 
LVAD centers is patient’s age as exclusion criteria for 
LVAD implantation. Several studies[8,10] have shown 
worse outcomes in older LVAD patients, although this 
was not observed in our analysis. In our 200 patient 
cohort, 14 patients were above the age of 70. Our 
oldest patient was 81 years. Survival at 2 years for 
patients above 70 was 62%. In addition, age was not 
found to be an independent predictor of survival. Other 
reports agree with our findings[34,35]. We feel that in 
appropriately selected patients, age should not be a 
contraindication to implantation[36].
Our study was not without limitations. Considering 
that this was not a prospective, randomize trial, it was 
subject to limitations inherent to any retrospective 
analysis. In addition statistical power was limited. 
Selection bias may also be present, since this is a single 
institution study. Finally, data on functional status and 
quality of life were not collected, which is an important 
target of LVAD therapy. 
for severe driveline and pocket infections. Our overall 
pump thrombosis rate was 6% (12/200), with 10/12 
(83%) of these incidence occurring between 2006-2012 
and only two cases of pump thrombosis over the past 
3 years. Based on initial reports that suggested that 
anticoagulation could be less aggressive for Heartmate 
II devices, we followed a less aggressive anticoagulation 
policy, which may explain the higher frequency of 
pump thrombosis during the first six years of our CF-
LVAD program. Since 2012, all patients receiving CF 
LVADs are postoperatively started on Asprin 81 mg and 
Warfarin with an INR target of 2.0-2.5. In addition we 
have recently been creating a larger sized pump pockets 
which reduces the effect of diaphragmatic excursion 
on the angle of the inflow cannula, thus reducing the 
incidence of pump thrombosis. Our driveline infection 
rate was only 7% which is significantly lower than the 
reported incidence of 20%[15]. It has been over 3 years 
since we have had a driveline infection. We feel that 
our success in preventing this challenging complication 
is linked with a new antibiotic and dressing protocol 
which was initiated at the end of 2011. The night before 
surgery patients are given 1.5 g of IV vancomycin, 2 g 
of IV cefepime, 400 mg IV Fluconazole and 600 mg of IV 
Rifampin. In penicillin or cephalosporin allergic patients, 
cefepime is substituted with 2 g of IV Aztreonam. 
Postoperatively, 4 doses of IV Vancomycin (15 mg/kg) 
every 12 h, 4 doses of IV Cefepime (2 g) every 12 h 
(or 2 daily doses of IV Aztreonam) and 2 daily doses 
of IV Fluconazole (400 mg) and IV Rifampin (600 mg) 
are administered. In the operating room, the drivelines 
are covered with Acticoat 3 Flex, which is a silver 
coated antimicrobial barrier that lasts for 3 d, followed 
by application of a tegaderm. Chlorhexidine and sterile 
water is used every 3 d to clean the driveline area, after 
which a new acticoat dressing is applied[5].
In our series, GIB was the most common adverse 
event (43/200, 21%), followed by RV failure (38/200, 
19%) and stroke (31/200, 15%) rates which are similar 
to previously published data[1,17-22]. The occurrence of 
GI bleeding makes postoperative LVAD management 
more challenging, as temporary discontinuation of 
anticoagulation is required, which may increase the 
risk of pump thrombosis and stroke. GI bleeding is 
also a common cause for early postoperative read-
mission[23]. The frequent association of GIB with CF 
LAVDs is presumed to be from the lack of pulsatility 
which causes AV malformations and angiodysplasia. A 
similar mechanism, known as Heyde’s syndrome[24], 
has been described in severe aortic stenosis, which 
also causes AV malformations and GIB. In addition, 
acquired von Willebrand syndrome has been reported 
as a potential cause for the development of GIB[25]. 
This frequent complication can be minimized through 
close INR monitoring, although recent studies have 
suggested that prophylactic administration of Octreotide 
may reduce the incidence of GIB[26,27]. RV failure is 
also a common LVAD related complication with a 
complex underlying mechanism. LV decompression 
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In conclusion, our single institutional analysis demon-
strates superb short and long term outcomes, up to 
4 year, with CF LAVDs. Compared to old generation 
devices, major adverse events such as pump throm-
bosis and driveline infections and frequent device 
exchanges, are now less frequent. Nevertheless, certain 
LVAD-related complications, such as GIB, stroke and 
RV failure do continue to occur. In addition to identifying 
new means of power transmission, new LVAD tech-
nology aims at reducing these adverse events. Preo-
perative hepatic and RV dysfunction appear to be 
predictors of post LVAD survival, which should certainly 
be taken into account in the patient selection process, 
whereas other significant variables, such as age, 
sex, etiology of heart failure, other comorbidities and 
reoperative cardiac surgery, do not appear to influence 
short and long term survival.
COMMENTS
Background
As the availability of left ventricular assist device (LVAD) therapy expands, there 
are still concerns regarding the relatively frequent occurrence of postoperative 
LVAD complications. Improvements are still required if LVADs are to become a 
plausible alternative to heart transplantation or a therapeutic option for patients 
in earlier stages of heart failure. The aim of this study was to review the authors’ 
institutional experience over 8 years with 200 continuous-flow (CF) LVADs.
 
Research frontiers
To our knowledge this is the largest single institutional CF LVAD report.
 
Innovations and breakthroughs
Their single institutional analysis demonstrates excellent short and long term 
outcomes, up to 4 years, with CF LAVDs. Compared to old generation devices, 
major adverse events such as pump thrombosis and driveline infections and 
frequent device exchanges, are now less frequent. Nevertheless, certain 
LVAD-related complications, such as gastrointestinal bleeding, stroke and right 
ventricular failure do continue to occur.
 
Applications
Post-operative management of LVADs and appropriate patient selection.
 
Terminology
CF LVADs: Continuous-flow left ventricular assist device. They are centrifugal or 
axial flow pumps that replace the function of the failing heart.
 
Peer-review
The authors present an interesting review of experience with LVAD and analytical 
results about postoperative prognosis.
REFERENCES
1 Park SJ, Milano CA, Tatooles AJ, Rogers JG, Adamson RM, 
Steidley DE, Ewald GA, Sundareswaran KS, Farrar DJ, Slaughter 
MS. Outcomes in advanced heart failure patients with left ventri­
cular assist devices for destination therapy. Circ Heart Fail 2012; 
5: 241­248 [PMID: 22282104 DOI: 10.1161/CIRCHEARTFAI­
LURE.111.963991]
2 Pagani FD, Miller LW, Russell SD, Aaronson KD, John R, Boyle 
AJ, Conte JV, Bogaev RC, MacGillivray TE, Naka Y, Mancini D, 
Massey HT, Chen L, Klodell CT, Aranda JM, Moazami N, Ewald 
GA, Farrar DJ, Frazier OH. Extended mechanical circulatory 
support with a continuous­flow rotary left ventricular assist device. 
 COMMENTS
Tsiouris A et al . Left ventricular assist device outcomes
800 November 26, 2015|Volume 7|Issue 11|WJC|www.wjgnet.com
W, Kirklin J, Pamboukian SV. Octreotide in the management of 
recurrent gastrointestinal bleed in patients supported by continuous 
flow left ventricular assist devices. ASAIO J 2015; 61: 107­109 
[PMID: 25232774 DOI: 10.1097/MAT.0000000000000143]
28 Moon MR, Bolger AF, DeAnda A, Komeda M, Daughters GT, 
Nikolic SD, Miller DC, Ingels NB. Septal function during left 
ventricular unloading. Circulation 1997; 95: 1320­1327 [PMID: 
9054866]
29 Tsiouris A, Paone G, Brewer RJ, Nemeh HW, Borgi J, Morgan JA. 
Outcomes of patients with right ventricular failure on milrinone after 
left ventricular assist device implantation. ASAIO J 2015; 61: 133­138 
[PMID: 25551415 DOI: 10.1097/MAT.0000000000000188]
30 Borgi J, Tsiouris A, Hodari A, Cogan CM, Paone G, Morgan JA. 
Significance of postoperative acute renal failure after continuous­flow 
left ventricular assist device implantation. Ann Thorac Surg 2013; 95: 
163­169 [PMID: 23103012 DOI: 10.1016/j.athoracsur.2012.08.076]
31 Ochiai Y, McCarthy PM, Smedira NG, Banbury MK, Navia JL, 
Feng J, Hsu AP, Yeager ML, Buda T, Hoercher KJ, Howard MW, 
Takagaki M, Doi K, Fukamachi K. Predictors of severe right 
ventricular failure after implantable left ventricular assist device 
insertion: analysis of 245 patients. Circulation 2002; 106: I198­I202 
[PMID: 12354733]
32 Sheikh FH, Russell SD. HeartMate® II continuous­flow left 
ventricular assist system. Expert Rev Med Devices 2011; 8: 11­21 
[PMID: 21158536 DOI: 10.1586/erd.10.77]
33 Popov AF, Hosseini MT, Zych B, Mohite P, Hards R, Krueger 
H, Bahrami T, Amrani M, Simon AR. Clinical experience with 
HeartWare left ventricular assist device in patients with end­
stage heart failure. Ann Thorac Surg 2012; 93: 810­815 [PMID: 
22289902 DOI: 10.1016/j.athoracsur.2011.11.076]
34 Allen JG, Kilic A, Weiss ES, Arnaoutakis GJ, George TJ, Shah 
AS, Conte JV. Should patients 60 years and older undergo bridge to 
transplantation with continuous­flow left ventricular assist devices? 
Ann Thorac Surg 2012; 94: 2017­2024 [PMID: 22858277 DOI: 
10.1016/j.athoracsur.2012.06.009]
35 Adamson RM, Stahovich M, Chillcott S, Baradarian S, Chammas 
J, Jaski B, Hoagland P, Dembitsky W. Clinical strategies and 
outcomes in advanced heart failure patients older than 70 years 
of age receiving the HeartMate II left ventricular assist device: 
a community hospital experience. J Am Coll Cardiol 2011; 57: 
2487­2495 [PMID: 21679851 DOI: 10.1016/j.jacc.2011.01.043]
36 Morgan JA, Nemeh HW, Paone G. Should left ventricular assist 
devices be implanted in patients seventy years of age and older: 
a comparative analysis. Heart Surg Forum 2014; 17: E182­E186 
[PMID: 25179968 DOI: 10.1532/HSF98.2014386]
P- Reviewer: Landesberg G, Ueda H    S- Editor: Qiu S 
L- Editor: A    E- Editor: Wu HL
16 Taghavi S, Ward C, Jayarajan SN, Gaughan J, Wilson LM, Mangi 
AA. Surgical technique influences HeartMate II left ventricular 
assist device thrombosis. Ann Thorac Surg 2013; 96: 1259­1265 
[PMID: 23968757 DOI: 10.1016/j.athoracsur.2013.05.081]
17 Morgan JA, Paone G, Nemeh HW, Henry SE, Patel R, Vavra J, 
Williams CT, Lanfear DE, Tita C, Brewer RJ. Gastrointestinal 
bleeding with the HeartMate II left ventricular assist device. J 
Heart Lung Transplant 2012; 31: 715­718 [PMID: 22425231 DOI: 
10.1016/j.healun.2012.02.015]
18 Tsukui H, Abla A, Teuteberg JJ, McNamara DM, Mathier MA, 
Cadaret LM, Kormos RL. Cerebrovascular accidents in patients 
with a ventricular assist device. J Thorac Cardiovasc Surg 2007; 
134: 114­123 [PMID: 17599496]
19 John R, Kamdar F, Liao K, Colvin­Adams M, Boyle A, Joyce L. 
Improved survival and decreasing incidence of adverse events with 
the HeartMate II left ventricular assist device as bridge­to­transplant 
therapy. Ann Thorac Surg 2008; 86: 1227­1234; discussion 1234­1235 
[PMID: 18805167 DOI: 10.1016/j.athoracsur.2008.06.030]
20 Kormos RL. The right heart failure dilemma in the era of left 
ventricular assist devices. J Heart Lung Transplant 2014; 33: 
134­135 [PMID: 24480446 DOI: 10.1016/j.healun.2013.12.019]
21 Farrar DJ. Ventricular interactions during mechanical circulatory 
support. Semin Thorac Cardiovasc Surg 1994; 6: 163­168 [PMID: 
7948293]
22 MacGowan GA, Schueler S. Right heart failure after left ventricular 
assist device implantation: early and late. Curr Opin Cardiol 2012; 27: 
296­300 [PMID: 22327288 DOI: 10.1097/HCO.0b013e3283511e60]
23 Tsiouris A, Paone G, Nemeh HW, Brewer RJ, Morgan JA. Factors 
determining post­operative readmissions after left ventricular assist 
device implantation. J Heart Lung Transplant 2014; 33: 1041­1047 
[PMID: 25034795 DOI: 10.1016/j.healun.2014.05.009]
24 Heyde EC. Sensitivity of bandpass filters using recirculating delay­
line structures. Appl Opt 1996; 35: 6945­6950 [PMID: 21151292 
DOI: 10.1364/AO.35.006945]
25 Meyer AL, Malehsa D, Budde U, Bara C, Haverich A, Strueber M. 
Acquired von Willebrand syndrome in patients with a centrifugal 
or axial continuous flow left ventricular assist device. JACC 
Heart Fail 2014; 2: 141­145 [PMID: 24720921 DOI: 10.1016/
j.jchf.2013.10.008]
26 Dang G, Grayburn R, Lamb G, Umpierrez De Reguero A, 
Gaglianello N. Octreotide for the Management of Gastrointestinal 
Bleeding in a Patient with a HeartWare Left Ventricular Assist 
Device. Case Rep Cardiol 2014; 2014: 826453 [PMID: 25587457 
DOI: 10.1155/2014/826453]
27 Loyaga-Rendon RY, Hashim T, Tallaj JA, Acharya D, Holman 
Tsiouris A et al . Left ventricular assist device outcomes
                                      © 2015 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
